Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
News|Podcasts|August 3, 2026
ACT Brief: Real-Time Monitoring Through Quick Wins, Consumer Wearable Validation Requirements, and Replimune RP1 Efficacy Data Advancement
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how a gradual, win-driven strategy scales real-time monitoring adoption, why consumer wearables need rigorous fit-for-purpose validation, and an FDA committee's favorable vote on Replimune's oncolytic virus combination therapy.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part five and final segment of his interview , Raviv Pryluk, CEO and co-founder of PhaseV, outlined a gradual, win-driven strategy for making real-time monitoring stick, starting in early phases and building toward pivotal trials with the right technology partners and a network effect that scales. Quick wins establish confidence and operational familiarity before broader rollout across therapeutic areas and study phases. - In a
contributed article from Signant Health , authors examined how consumer-grade wearables offer burden reduction and engagement benefits but show heterogeneous accuracy across devices and endpoints. Integration into regulated trials requires rigorous fit-for-purpose validation, careful endpoint selection, standardized use protocols, and ongoing performance monitoring to align data quality with regulatory expectations. FDA's advisory committee voted 10 to 3 that efficacy results from Replimune's Ignyte study are evaluable and clinically meaningful for RP1 in combination with nivolumab for anti-PD-1 refractory advanced melanoma. The favorable vote follows two prior complete response letters and supports the company's resubmitted biologics license application ahead of an August 2 target action date.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Trending on Applied Clinical Trials Online
1
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
2
What It Takes to Harmonize AI Across Fragmented Oncology Health Systems
3
Using AI to Design Better Trials Before the First Patient Enrolls: Q&A with Claire Riches, Citeline
4
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
5